Meldonium - Grindeks
Alternative Names: Kvaterin; MET-88; Mildronate; QuaterinLatest Information Update: 04 Jul 2016
At a glance
- Originator Latvian Institute of Organic Synthesis
- Developer Grindeks; Taiho Pharmaceutical
- Class Adjuvants; Antiarrhythmics; Cardiotonics; Ischaemic heart disorder therapies; Methylhydrazines; Propionates; Small molecules; Vasodilators
- Mechanism of Action Gamma-butyrobetaine dioxygenase inhibitors; Partial fatty acid oxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heart failure; Ischaemic heart disorders
- No development reported Angina pectoris; Arrhythmias
Most Recent Events
- 04 Jul 2016 Phase III development is ongoing in China
- 30 May 2014 Phase-III clinical trials in Heart failure in China (IV)
- 30 May 2014 Phase-III clinical trials in Heart failure in China (PO)